Director Dealing

RNS Number : 6549Z

BiVictriX Therapeutics PLC

15 September 2022

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

Director Dealing

Alderley Park, 15 September 2022 BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, announces the following dealing in the Company's ordinary shares of 1 pence each ("Ordinary Shares").

On 13 September 2022, Dr Michael Kauffman, a Non-Executive Director of the Company, purchased 75,000 Ordinary Shares at a price of US$0.25 each.

Following the transaction, Dr Kauffman is benefically interested in [75,000] Ordinary Shares, representing [0.11]% of the Company's total issued share capital.  

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Michael Kauffman
2.	Reason for the Notification
a)	Position/status	Non-Executive Director
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	BiVictriX Therapeutics plc
b)	LEI	213800ZI85IZNA6N3L53
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 1 pence each GB00BNXH3K91
	Identification code
b)	Nature of the transaction	Purchase of 75,000 Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) US$0.25 75,000
d)	Aggregated information: -   Aggregated volume -   Price	Price(s) Volume(s) US$0.25 75,000
e)	Date of the transaction	13 September 2022
f)	Place of the transaction	AIM, London Stock Exchange

-Ends-

For more information, please contact: BiVictriX Therapeutics plc Tiffany Thorn, Chief Executive Officer Iain Ross, Chairman Email: [e-mail] SP Angel Corporate Finance LLP (NOMAD and Broker) Tel: [phone] David Hignell, Caroline Rowe (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking) Panmure Gordon (UK) Limited (Joint Broker) Tel: [phone] Rupert Dearden, Freddy Crossley, Emma Earl Consilium Strategic Communications Mary-Jane Elliott, Genevieve Wilson, Alex Gunter Tel: [phone] Email: [e-mail]

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related harmful side effects. This provides the opportunity for clinicians to give much higher, more effective doses of treatment to patients without significantly harming the patient in the process. 

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® therapeutics which are designed to selectively target cancer-specific antigen pairs, or "twin antigens fingerprints", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting, where it offers the opportunity to be a game-changing approach to cancer care.

BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens fingerprints" across a broad range of cancer indications. The Company is using these novel twin antigens to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

 

END

 

 

DSHGPUAWBUPPGCA